Menu
05/12/2022
Break-Out QUB Firm Secures £10m Research Investment
Re-Vana Therapeutics, one of QUB's technology spin-out companies, has attracted £10m of investment for research into sight-threatening eye disease.
The company's innovative method of sustained-release therapeutics can replace regular invasive treatment, increasing the quality of care for patients.
The investment comes from a financing round led by Visionary Ventures with additional US investors ExSight Ventures, InFocus Capital Partners and existing UK investors TechStart Ventures, Co Fund NI and Qubis Ltd.
In conjunction with this financing, Re-Vana's Board of Directors and Scientific Advisory Board have been further strengthened by the appointment of Robert Avery MD of Visionary Ventures to the Board of Directors and Michael O'Rourke as Board Chair.
Speaking about the investment, Michael O'Rourke, President, Chief Executive Officer and Board Chair of Re-Vana Therapeutics said: "Financing from new and existing investors during this challenging time is a testament to the potential of Re-Vana's technologies for sustained delivery of biologic therapeutics.
"We are especially fortunate to have received financing from multiple, highly-respected, US ophthalmic-focused venture capital firms and UK investors. Their proven knowledge and expertise in ophthalmology are invaluable additions to Re-Vana as we accelerate the development of our biologic therapeutics pipeline and expand our strategic partnerships."
Re-Vana was cofounded by Professor Raj Thakur and Queen's University Pro-Vice-Chancellor Professor David Jones. Welcoming the multi million pound investment, Professor Jones said: "This multi million pound investment reflects the expertise and innovation that Northern Ireland generates and we are delighted that Re-Vana can continue its ground breaking work in ophthalmology.
"Queen's University is a driver of innovation and talent and we are proud of our research and academic excellence as societal and economic drivers in Belfast, Northern Ireland and across the globe."
Professor Raj Thakur added: "There has been a longstanding challenge in maintaining the necessary drug levels to treat a range of ocular diseases without frequent administrations. Our novel concept of photocrosslinked drug delivery systems means the need for intravitreal injections can be greatly reduced, decreasing the burden on patients and healthcare systems.
"Re-Vana was established to focus on the development of internal therapeutics as well as external strategic collaborations with industry and, to date has raised more than $17.75M to support the development of sustained release biologics."
On behalf of Queen's QUBIS has supported over 100 spin-out companies which raise millions of pounds of investment, creating thousands of jobs. QUBIS CEO Brian McCaul said: "We are proud to have helped form Re-Vana, becoming their first investor and continuing to show our support in each round. To see this company attract investment for so many US based specialist Ophthalmology funds is a testament to the innovative potential of Queen's research and Northern Ireland innovation capability."
The company's innovative method of sustained-release therapeutics can replace regular invasive treatment, increasing the quality of care for patients.
The investment comes from a financing round led by Visionary Ventures with additional US investors ExSight Ventures, InFocus Capital Partners and existing UK investors TechStart Ventures, Co Fund NI and Qubis Ltd.
In conjunction with this financing, Re-Vana's Board of Directors and Scientific Advisory Board have been further strengthened by the appointment of Robert Avery MD of Visionary Ventures to the Board of Directors and Michael O'Rourke as Board Chair.
Speaking about the investment, Michael O'Rourke, President, Chief Executive Officer and Board Chair of Re-Vana Therapeutics said: "Financing from new and existing investors during this challenging time is a testament to the potential of Re-Vana's technologies for sustained delivery of biologic therapeutics.
"We are especially fortunate to have received financing from multiple, highly-respected, US ophthalmic-focused venture capital firms and UK investors. Their proven knowledge and expertise in ophthalmology are invaluable additions to Re-Vana as we accelerate the development of our biologic therapeutics pipeline and expand our strategic partnerships."
Re-Vana was cofounded by Professor Raj Thakur and Queen's University Pro-Vice-Chancellor Professor David Jones. Welcoming the multi million pound investment, Professor Jones said: "This multi million pound investment reflects the expertise and innovation that Northern Ireland generates and we are delighted that Re-Vana can continue its ground breaking work in ophthalmology.
"Queen's University is a driver of innovation and talent and we are proud of our research and academic excellence as societal and economic drivers in Belfast, Northern Ireland and across the globe."
Professor Raj Thakur added: "There has been a longstanding challenge in maintaining the necessary drug levels to treat a range of ocular diseases without frequent administrations. Our novel concept of photocrosslinked drug delivery systems means the need for intravitreal injections can be greatly reduced, decreasing the burden on patients and healthcare systems.
"Re-Vana was established to focus on the development of internal therapeutics as well as external strategic collaborations with industry and, to date has raised more than $17.75M to support the development of sustained release biologics."
On behalf of Queen's QUBIS has supported over 100 spin-out companies which raise millions of pounds of investment, creating thousands of jobs. QUBIS CEO Brian McCaul said: "We are proud to have helped form Re-Vana, becoming their first investor and continuing to show our support in each round. To see this company attract investment for so many US based specialist Ophthalmology funds is a testament to the innovative potential of Queen's research and Northern Ireland innovation capability."
Related Northern Ireland News Stories
Click here for the latest headlines.
14 November 2024
Minister Murphy Raises Economic Concerns in London
Economy Minister Conor Murphy today raised a number of key economic issues with British Government Ministers during a visit to London.
Minister Murphy Raises Economic Concerns in London
Economy Minister Conor Murphy today raised a number of key economic issues with British Government Ministers during a visit to London.
09 December 2013
Community Projects Receive £1.1m
A total of 16 community groups across Belfast have received total funding of just over £1.1m from City Council. The funding boost is being delivered through the £5m Local Investment Fund (LIF), which is part of the council's wider Investment Programme for the city. The move brings the overall amount allocated through the fund to over £2.
Community Projects Receive £1.1m
A total of 16 community groups across Belfast have received total funding of just over £1.1m from City Council. The funding boost is being delivered through the £5m Local Investment Fund (LIF), which is part of the council's wider Investment Programme for the city. The move brings the overall amount allocated through the fund to over £2.
16 May 2013
£1.25m For Belfast Community Projects
20 community regeneration projects across Belfast have received funding totalling £1.25m from the City Council. The funding is part of £5m set aside for the Local Investment Fund (LIF). Just under £1.3m is earmarked each to the North, South, East and West of the city and a further £490,000 allocated for the Shankill area.
£1.25m For Belfast Community Projects
20 community regeneration projects across Belfast have received funding totalling £1.25m from the City Council. The funding is part of £5m set aside for the Local Investment Fund (LIF). Just under £1.3m is earmarked each to the North, South, East and West of the city and a further £490,000 allocated for the Shankill area.
08 November 2018
MLA's Condemn Findings Of Social Investment Fund Audit
Local politicians have condemned the recent findings of the independent NI Office Report into the Social Investment Fund (SIF) and branded it the next RHI inquiry. The audit uncovered evidence of poor governance of the £93 million fund, along with conflicts of interest and a lack of transparency and accountability.
MLA's Condemn Findings Of Social Investment Fund Audit
Local politicians have condemned the recent findings of the independent NI Office Report into the Social Investment Fund (SIF) and branded it the next RHI inquiry. The audit uncovered evidence of poor governance of the £93 million fund, along with conflicts of interest and a lack of transparency and accountability.
16 May 2017
Queen's To Disinvest From Fossil Fuels
Queen's University in Belfast has confirmed it is to disinvest from fossil fuels. The University has updated its investment policy and will, subject to no detrimental impact on expected investment returns, seek to disinvest from companies involved in the extraction and production of fossil fuels by 2025.
Queen's To Disinvest From Fossil Fuels
Queen's University in Belfast has confirmed it is to disinvest from fossil fuels. The University has updated its investment policy and will, subject to no detrimental impact on expected investment returns, seek to disinvest from companies involved in the extraction and production of fossil fuels by 2025.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
